Display options
Share it on

Open Forum Infect Dis. 2020 Jan 27;7(1):ofz554. doi: 10.1093/ofid/ofz554. eCollection 2020 Jan.

Inpatient Management of Uncomplicated Skin and Soft Tissue Infections in 34 Veterans Affairs Medical Centers: A Medication Use Evaluation.

Open forum infectious diseases

Jesse D Sutton, Ronald Carico, Muriel Burk, Makoto M Jones, XiangMing Wei, Melinda M Neuhauser, Matthew Bidwell Goetz, Kelly L Echevarria, Emily S Spivak, Francesca E Cunningham,

Affiliations

  1. Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah, USA.
  2. VA Salt Lake City Informatics Decision-Enhancement and Analytic Sciences Center (IDEAS 2.0), Salt Lake City, Utah, USA.
  3. Center for Medication Safety, Hines VA, Hines, Illinois, USA.
  4. VA Pharmacy Benefits Management Services, Hines VA, Hines, Illinois, USA.
  5. Department of Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
  6. Veterans Affairs Greater Lost Angeles Healthcare System, Los Angeles, California, USA.
  7. David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.
  8. Department of Medicine, Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, Utah, USA.

PMID: 32010738 PMCID: PMC6984672 DOI: 10.1093/ofid/ofz554

Abstract

BACKGROUND: Skin and soft tissue infections (SSTIs) are a key antimicrobial stewardship target because they are a common infection in hospitalized patients, and non-guideline-concordant antibiotic use is frequent. To inform antimicrobial stewardship interventions, we evaluated the proportion of veterans hospitalized with SSTIs who received guideline-concordant empiric antibiotics or an appropriate total duration of antibiotics.

METHODS: A retrospective medication use evaluation was performed in 34 Veterans Affairs Medical Centers between 2016 and 2017. Hospitalized patients who received antibiotics for uncomplicated SSTI were included. Exclusion criteria were complicated SSTI, severe immunosuppression, and antibiotics for any non-SSTI indication. Data were collected by manual chart review. The primary outcome was the proportion of patients receiving both guideline-concordant empiric antibiotics and appropriate treatment duration, defined as 5-10 days of antibiotics. Data were analyzed and reported using descriptive statistics.

RESULTS: Of the 3890 patients manually evaluated for inclusion, 1828 patients met inclusion criteria. There were 1299 nonpurulent (71%) and 529 purulent SSTIs (29%). Overall, 250 patients (14%) received guideline-concordant empiric therapy and an appropriate duration. The most common reason for non-guideline-concordance was receipt of antibiotics targeting methicillin-resistant

CONCLUSIONS: We identified 3 common opportunities to improve antibiotic use for patients hospitalized with uncomplicated SSTIs: use of anti-MRSA antibiotics in patients with nonpurulent SSTIs, use of broad-spectrum Gram-negative antibiotics, and prolonged durations of therapy.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.

Keywords: abscess; antibiotic stewardship; cellulitis; skin and soft tissue infections

References

  1. BMJ Open. 2017 Mar 17;7(3):e013260 - PubMed
  2. Clin Infect Dis. 2018 Oct 30;67(10):1550-1558 - PubMed
  3. JAMA. 2014 Oct 8;312(14):1438-46 - PubMed
  4. Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S47-S53 - PubMed
  5. Infect Control Hosp Epidemiol. 2014 Oct;35(10):1241-50 - PubMed
  6. J Am Acad Dermatol. 2015 Jul;73(1):70-5 - PubMed
  7. Arch Intern Med. 2011 Jun 27;171(12):1072-9 - PubMed
  8. JAMA Dermatol. 2018 May 1;154(5):529-536 - PubMed
  9. Clin Infect Dis. 2018 Aug 16;67(5):657-666 - PubMed
  10. Clin Infect Dis. 2016 Oct 15;63(8):1034-1041 - PubMed
  11. Clin Infect Dis. 2017 Jan 15;64(2):214-217 - PubMed
  12. JAMA. 2017 May 23;317(20):2088-2096 - PubMed
  13. JAMA. 2019 Jan 15;321(2):188-199 - PubMed
  14. BMC Infect Dis. 2016 Nov 29;16(1):721 - PubMed
  15. Arch Intern Med. 2004 Aug 9-23;164(15):1669-74 - PubMed
  16. J Antimicrob Chemother. 2013 Oct;68(10):2393-9 - PubMed
  17. Clin Infect Dis. 2010 Sep 15;51(6):641-50 - PubMed
  18. J Clin Microbiol. 2003 Jun;41(6):2275-8 - PubMed
  19. Medicine (Baltimore). 2010 Jul;89(4):217-26 - PubMed
  20. N Engl J Med. 2006 Aug 17;355(7):666-74 - PubMed
  21. JAMA Intern Med. 2018 Jul 1;178(7):994-996 - PubMed
  22. N Engl J Med. 2011 Apr 14;364(15):1419-30 - PubMed
  23. JAMA. 2013 Feb 13;309(6):559-69 - PubMed
  24. Thromb Res. 2013 Sep;132(3):336-40 - PubMed
  25. Clin Infect Dis. 2008 Sep 15;47(6):735-43 - PubMed
  26. Clin Microbiol Infect. 2013 Sep;19(9):E377-85 - PubMed
  27. Clin Infect Dis. 2013 Jun;56(12):1754-62 - PubMed
  28. Am J Emerg Med. 2016 Jun;34(6):957-62 - PubMed
  29. Am J Emerg Med. 2017 Feb;35(2):249-254 - PubMed
  30. JAMA. 2012 Aug 1;308(5):502-11 - PubMed
  31. Ann Intern Med. 2005 Jan 4;142(1):47-55 - PubMed
  32. JAMA Intern Med. 2017 Sep 1;177(9):1308-1315 - PubMed
  33. Clin Infect Dis. 2014 Jul 15;59(2):e10-52 - PubMed
  34. Clin Microbiol Infect. 2018 Oct;24(10):1084-1088 - PubMed
  35. Clin Infect Dis. 2009 Oct 1;49(7):1025-35 - PubMed
  36. PLoS One. 2018 Sep 27;13(9):e0204036 - PubMed
  37. Clin Infect Dis. 2011 Feb 1;52(3):e18-55 - PubMed
  38. Clin Infect Dis. 2005 Nov 15;41(10):1373-406 - PubMed
  39. Lancet Infect Dis. 2014 Aug;14(8):696-705 - PubMed

Publication Types